Copaxone (Co-PAX-ohn, copolymer-1 or "cop-1")

September 1996

Patients with multiple sclerosis will be asking about Copaxone (Co-PAX-ohn, copolymer-1 or "cop-1"). An FDA committee will review it this month. They'll most probably advise approval for patients with relapsing forms of MS.

Copaxone suppresses the immune response that leads to neurological damage. It reduces relapse rates...and might slow disability.

We'll fill you in on more details when it gets approved.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote